Méthyltestostérone : interactions médicamenteuses

These drugs include, but are not limited to, the following: the anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, phenytoin the androgen receptor inhibitor enzalutamide the antimycobacterials rifampin, rifapentine the cytotoxic agent mitotane St. (notice Doravirine, Contre-indications)

Because of the ability of Type II 5α-reductase inhibitors to inhibit the conversion of testosterone to 5α-dihydrotestosterone (DHT), finasteride may cause abnormalities of the external genitalia of a male fetus of a pregnant female who receives finasteride. (notice Finastéride, Contre-indications)

CONTRAINDICATIONS: Precocious puberty, prostatic carcinoma or other androgen-dependent neoplasm, prior allergic reaction to HCG. (notice Gonadotrophine chorionique, Contre-indications)

To date, epidemiologic studies and randomized controlled trials have been inconclusive for determining the risk of major adverse cardiovascular events (MACE), such as non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death, with the use of testosterone compared to non-use. (notice Méthyltestostérone, Mises en garde)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (notice Méthyltestostérone, Interactions médicamenteuses)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (notice Méthyltestostérone, Interactions médicamenteuses)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (notice Méthyltestostérone, Mises en garde)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (notice Méthyltestostérone, Mises en garde)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (notice Méthyltestostérone, Mises en garde)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (notice Méthyltestostérone, Interactions médicamenteuses)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (notice Méthyltestostérone, Mises en garde)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (notice Méthyltestostérone, Mises en garde)

PRECAUTIONS General Induction of androgen secretion by hCG may cause fluid retention. (notice Choriogonadotropine alfa, Précautions)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (notice Méthyltestostérone, Mises en garde)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (notice Méthyltestostérone, Mises en garde)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (notice Méthyltestostérone, Interactions médicamenteuses)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (notice Méthyltestostérone, Mises en garde)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (notice Méthyltestostérone, Mises en garde)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (notice Méthyltestostérone, Mises en garde)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (notice Méthyltestostérone, Interactions médicamenteuses)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (notice Méthyltestostérone, Interactions médicamenteuses)

Free hormone concentrations, such as testosterone and estradiol, may be decreased. (notice Estradiol et noréthistérone, Mises en garde et précautions)

Free hormone concentrations, such as testosterone and estradiol, may be decreased. (notice Estrogènes conjugués, Précautions)

Free hormone concentrations, such as testosterone and estradiol, may be decreased. (notice Estrogènes conjugués et bazédoxifène, Mises en garde et précautions)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (notice Méthyltestostérone, Mises en garde)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (notice Méthyltestostérone, Mises en garde)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (notice Méthyltestostérone, Mises en garde)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (notice Méthyltestostérone, Mises en garde)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (notice Méthyltestostérone, Mises en garde)

For Men : Clinical monitoring for spermatogenesis utilizes the following indirect or direct measures: Serum testosterone level Semen analysis 5.11 FOLLISTIM Pen The FOLLISTIM Pen is intended only for use with FOLLISTIM AQ Cartridge. (notice Follitropine, Mises en garde et précautions)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (notice Méthyltestostérone, Interactions médicamenteuses)

…medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H 2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs… (notice Glimépiride, Interactions médicamenteuses)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (notice Goséréline, Mises en garde et précautions)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (notice Méthyltestostérone, Mises en garde)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (notice Méthyltestostérone, Interactions médicamenteuses)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (notice Méthyltestostérone, Mises en garde)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (notice Méthyltestostérone, Interactions médicamenteuses)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (notice Méthyltestostérone, Interactions médicamenteuses)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (notice Méthyltestostérone, Interactions médicamenteuses)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (notice Méthyltestostérone, Interactions médicamenteuses)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (notice Méthyltestostérone, Interactions médicamenteuses)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (notice Méthyltestostérone, Interactions médicamenteuses)

Tumor Flare: Increased serum testosterone (~ 50% above baseline) may occur when initiating treatment with LUPRON DEPOT. (notice Leuproréline, Mises en garde et précautions)

Androgens/Anabolic Steroids Asparaginase Glucocorticoids Slow-Release Nictonic Acid These drugs may decrease serum TBG concentration. (notice Lévothyroxine, Interactions médicamenteuses)

Androgens/Anabolic Steroids Asparaginase Glucocorticoids Slow-Release Nicotinic Acid These drugs may decrease serum TBG concentration. (notice Liothyronine, Interactions médicamenteuses)

However, clinical studies have shown that lovastatin does not reduce basal plasma cortisol concentration or impair adrenal reserve, and does not reduce basal plasma testosterone concentration. (notice Lovastatine, Interactions médicamenteuses)

The following laboratory tests may be affected by progestins including MPA Injectable Suspension, USP: (a) Plasma and urinary steroid levels are decreased (e.g., progesterone, estradiol, pregnanediol, testosterone, cortisol). (notice Médroxyprogestérone, Interactions médicamenteuses)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (notice Méthyltestostérone, Mises en garde)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (notice Méthyltestostérone, Mises en garde)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (notice Méthyltestostérone, Mises en garde)

…anti-diabetic medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs… (notice Pioglitazone et glimépiride, Interactions médicamenteuses)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (notice Méthyltestostérone, Mises en garde)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (notice Méthyltestostérone, Mises en garde)

Reproductive effects: Include decreased testosterone and increased prolactin levels. (notice Rameltéon, Mises en garde et précautions)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (notice Méthyltestostérone, Interactions médicamenteuses)

Abiraterone: Spironolactone binds to the androgen receptor and may increase prostate‑specific antigen (PSA) levels in abiraterone-treated prostate cancer patients. (notice Spironolactone et hydrochlorothiazide, Interactions médicamenteuses)

Hypercalcemia in Patients with Metastatic Breast Cancer As with other additive hormonal therapy (estrogens and androgens), hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with tamoxifen. (notice Tamoxifène, Mises en garde et précautions)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (notice Méthyltestostérone, Interactions médicamenteuses)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (notice Méthyltestostérone, Mises en garde)

Tumor Flare: Transient increase in serum testosterone levels can occur within the first few weeks of treatment. (notice Triptoréline, Mises en garde et précautions)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (notice Méthyltestostérone, Interactions médicamenteuses)

In addition to discontinuation of the drug, diuretic therapy may be required. (notice Méthyltestostérone, Mises en garde)

In addition to discontinuation of the drug, diuretic therapy may be required. (notice Méthyltestostérone, Mises en garde)

In addition to discontinuation of the drug, diuretic therapy may be required. (notice Méthyltestostérone, Mises en garde)

In addition to discontinuation of the drug, diuretic therapy may be required. (notice Méthyltestostérone, Mises en garde)

In addition to discontinuation of the drug, diuretic therapy may be required. (notice Méthyltestostérone, Mises en garde)

In addition to discontinuation of the drug, diuretic therapy may be required. (notice Méthyltestostérone, Mises en garde)

In addition to discontinuation of the drug, diuretic therapy may be required. (notice Méthyltestostérone, Mises en garde)

In addition to discontinuation of the drug, diuretic therapy may be required. (notice Méthyltestostérone, Mises en garde)

In addition to discontinuation of the drug, diuretic therapy may be required. (notice Méthyltestostérone, Mises en garde)

In addition to discontinuation of the drug, diuretic therapy may be required. (notice Méthyltestostérone, Mises en garde)

In addition to discontinuation of the drug, diuretic therapy may be required. (notice Méthyltestostérone, Mises en garde)

In addition to discontinuation of the drug, diuretic therapy may be required. (notice Méthyltestostérone, Mises en garde)

In addition to discontinuation of the drug, diuretic therapy may be required. (notice Méthyltestostérone, Mises en garde)

In addition to discontinuation of the drug, diuretic therapy may be required. (notice Méthyltestostérone, Mises en garde)

In addition to discontinuation of the drug, diuretic therapy may be required. (notice Méthyltestostérone, Mises en garde)

In addition to discontinuation of the drug, diuretic therapy may be required. (notice Méthyltestostérone, Mises en garde)

In addition to discontinuation of the drug, diuretic therapy may be required. (notice Méthyltestostérone, Mises en garde)

Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. (notice Méthyltestostérone, Précautions)

In addition to discontinuation of the drug, diuretic therapy may be required. (notice Méthyltestostérone, Mises en garde)

In addition to discontinuation of the drug, diuretic therapy may be required. (notice Méthyltestostérone, Mises en garde)

In addition to discontinuation of the drug, diuretic therapy may be required. (notice Méthyltestostérone, Mises en garde)

In addition to discontinuation of the drug, diuretic therapy may be required. (notice Méthyltestostérone, Mises en garde)

In addition to discontinuation of the drug, diuretic therapy may be required. (notice Méthyltestostérone, Mises en garde)

In addition to discontinuation of the drug, diuretic therapy may be required. (notice Méthyltestostérone, Mises en garde)

Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. (notice Méthyltestostérone, Précautions)

In addition to discontinuation of the drug, diuretic therapy may be required. (notice Méthyltestostérone, Mises en garde)

In addition to discontinuation of the drug, diuretic therapy may be required. (notice Méthyltestostérone, Mises en garde)

In addition to discontinuation of the drug, diuretic therapy may be required. (notice Méthyltestostérone, Mises en garde)

Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. (notice Méthyltestostérone, Précautions)

Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. (notice Méthyltestostérone, Précautions)

In addition to discontinuation of the drug, diuretic therapy may be required. (notice Méthyltestostérone, Mises en garde)

In addition to discontinuation of the drug, diuretic therapy may be required. (notice Méthyltestostérone, Mises en garde)

In addition to discontinuation of the drug, diuretic therapy may be required. (notice Méthyltestostérone, Mises en garde)

In addition to discontinuation of the drug, diuretic therapy may be required. (notice Méthyltestostérone, Mises en garde)